Use the hyperlinks, where available to access additional clinical trial information.
A Phase II randomised trial comparing immune priming by low dose oral cyclophosphamide plus olaparib versus priming by olaparib alone, prior to combination therapy with olaparib plus durvalumab, versus single agent olaparib alone, in asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with homologous recombination repair defects
Other Non-Commercial Sponsor
University of Sydney
Participants will be randomised to receive treatment according to one of the following three groups: (1) Olaparib and cyclophosphamide (50mg daily) followed by olaparib and durvalumab (1500mg every 4 weeks for 12 cycles), or (2) Olaparib followed by olaparib and durvalumab (as above), or (3) Olaparib alone. In each group, 300mg Olaparib will be administered orally, twice daily until progression occurs.